Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 9009 results

  1. Orbital atherectomy for calcified coronary artery disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Multi-vessel minimal access coronary artery surgery for multi-vessel coronary artery disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. MRI guided transurethral high intensity ultrasound ablation of the prostate

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Coronary venous arterialisation in patients with refractory angina

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. EchoLaser percutaneous laser ablation treatment for patients with neck lesions

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Pancreas SABR

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Stockholm3 blood test for prostate cancer, (MT734),

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  8. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  9. Spartan RX point-of-care CYP2C19 test

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  10. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]

    Awaiting development Reference number: GID-TA11879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    Awaiting development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    Awaiting development